Pharmacokinetics of artemisinin-type compounds

Clinical Pharmacokinetics

Volumn 39, Issue 4, 2000, Pages 255-270

  Navaratnam, Visweswaran ^a   Mansor, Sharif Mahsufi ^a   Sit, Nain Weng ^a   Grace, James ^b   Li, Qigui ^b   Olliaro, Piero ^c  

^a SCHOOL OF PHYSICS   (Malaysia)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEETHER; ARTELINIC ACID; ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; DIHYDROARTEMISININ; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; FIRST PASS EFFECT; HUMAN; MALARIA; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 0033760106     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039040-00002     Document Type: Review

References (123)

1. Luo XD, Shen CC. The chemistry, pharmacology, and clinical applications of qinghaosu (artemisinin) and its derivatives. Med Res Rev 1987; 7: 29-52
2. Barraddl LB, Fitton A. Artesunate: a review of its pharmacology and therapeutic efficacy in treatment of malaria. Drugs 1995: 50 (4): 714-41
3. de Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996; 52 (6): 818-36
4. Smith DA, van de Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr Opin Chem Biol 1999; 3: 373-8
5. Maggs JL, Madden S, Bishop LP, et al. The rat biliary excretion of dihydroartemisinin, an antimalarial endoperoxide. Drug Metab Dispos 1997; 25 (10): 1200-4
6. Batty KT, Ilett KF, Edwards G, et al. Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomes. Br J Pharmacol 1998; 125(1): 159-67
7. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999; 37 (2): 105-25
8. Titulaer HA, Zuidema J, Kager PA, et al. The pharmacokinetics of artemisinin after oral, intramuscular and rectal administration to volunteers. J Pharm Pharmacol 1990; 42 (11): 810-3
9. Ashton M, Gordi T, Trinh Nh, et al. Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. Biopharm Drug Dispos 1998; 19: 245-50
10. Sidhu JS, Ashton M, Huong NV, et al. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol 1998; 45: 347-54
11. Ashton M, Sy ND, Van Huong N, et al. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 1998; 63 (4): 482-93
12. Koopmans R, Duc DD, Kager PA, et ai. The pharmacokinetics of artemisinin suppositories in Vietnamese patients with malaria. Trans R Soc Trop Med Hyg 1998; 92: 434-6
13. Koopmans R, Ha LD, Duc DD, et al. The pharmacokinetics of artemisinin after administration of two different suppositories to healthy Vietnamese subjects. Am J Trop Med Hyg 1999; 60: 244-7
14. Navaratnam V, Mansor SM, Mordi MN, et al. Comparative pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy volunteers. Eur J Clin Pharmacol 1998; 54: 411-4
15. Looareesuwan S, Wilairatana P. The rational use of qinghaosu and its derivatives: what is the future of new compounds? Med Trop 1998; 58 Suppl. 3: 89S-92S
16. Li GQ, Wang XH, Gui XB, et al. Dose findings of dihydroartemisinin in treatment of falciparum malaria. Southeast Asian J Trop Med Public Health 1999; 30 (1): 17-9
17. Wilairatana P, Chanthavanich P, Singhasivanon P, et al. A comparison of three different dihydroartemisinin formulations for the treatment of acute uncomplicated falciparum malaria in Thailand. Int J Parasitol 1998; 28: 1213-8
18. Looareesuwan S, Wilairatana P, Vanijanonta S, et al. Treatment of acute, uncomplicated falciparum malaria with oral dihydroartemisinin. Ann Trop Med Parasitol 1996; 90: 21-8
19. Li Q-G, Peggins JO, Fleckenstein LL, et al. The pharmacokinetics and bioavailability of dihydroartemisinin arteether, artemether, artesunic and arteline acid in rats. J Pharm Pharmacol 1998; 50: 173-82
20. Melendez V, Peggins JO, Brewer TG, et al. Determination of the antimalarial arteether and its deethylated metabolite dihydroartemisinin in plasma by high-performance liquid chromatography with reductive electrochemical detection. J Pharmacol Sci 1991; 80: 132-8
21. Li Q-G, Brueckner RP, Peggins JO, et al. Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses. Eur J Drug Metab Pharmacokinet 1999; 24 (3): 213-23
22. Benakis A, Paris M, Plessas C, et al. Pharmacokinetics of sodium artesunate after im and iv administration [abstract]. Am J Trop Med Hyg 1993; 49 Suppl.: 293
23. Batty KT, Thu LT, Davis TM, et al. A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Br J Clin Pharmacol 1998; 45: 123-9
24. Batty KT, Le AT, Ilett KF, et al. A pharmacokinetic and pharmacodynamics study of artesunate for vivax malaria. Am J Trop Med Hyg 1998; 59: 823-7
25. Newton P, Suputtamongkol Y, Teja-Isavadharm P, et al. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44: 972-7
26. Teja-Isavadharm P, Nosten F, Kyle DE, et al. Comparative bioavailability of rectal, rectal, and intramuscular artemethcr in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br J Clin Pharmacol 1996; 42: 599-604
27. Karbwang J, Na-Bangchang K, Congpuong K, et al. Pharmacokinetics and bioavailability of oral and intramuscular artemether. Eur J Clin Pharmacol 1997; 52: 307-10
28. Murphy SA, Mberu E, Muhia D, et al. The disposition of intramuscular artemether in children with cerebral malaria: a preliminary study. Trans R Soc Trop Med Hyg 1997; 91 (3): 331-4
29. Niu X, Ho L, Ren Z, et al. Metabolic fate of qinghaosu in rats: a new tlc densitometric method for its determination in biological material. Eur J Drug Metab Pharmacokinet 1985; 10: 55-9
30. Zhao KC, Song ZY. Distribution and excretion of artesunate in rats. Proc Chin Acad Med Sci Peking Union Med Coll 1989; 4(4): 186-8
31. Jiang JR, Zou CD, Shu HL, et al. Assessment of absorption and distribution of artemether in rats using a thin layer chromatography scanning technique. Acta Pharmacol Sin 1989; 10 (5): 431-4
32. 14C-artelinic acid in rats. Birmingham (AL): Southern Research Institute, 1998 (Data on file)
33. 14C-artelinic acid in rats. Birmingham (AL): Southern Research Institute, 1998 (Data on file)
34. Edlund PO, Westerlund D, Carlqvist J, et al. Determination of artesunate and dihydroartemisinin in plasma by liquid chromatography with post-column derivatization and UV detection. Acta Pharm Sci 1984; 21: 223-34
35. 14C-dihydroartemisinin to plasma proteins and red blood cells of human and animal species in vivo and in vitro, [abstract PpA 144]. 21st Annual Meeting of the Society for Experimental Biology; 1998; San Francisco
36. Li QG, Peggins JO, Lin AJ, et al. Pharmacology and toxicology of artelinic acid: preclinical investigations on pharmacokinetics, metabolism, protein and red blood cell binding, and acute and anorectic toxicities. Trans R Soc Trop Med Hyg 1998; 92 (3): 332-40
37. Bakhshi HB, Gordi T, Ashton M. In vitro interaction of artemisinin with intact human erythrocytes, erythrocyte ghosts, haemoglobin and carbonic anhydrase. J Pharm Pharmacol 1997: 49 (2): 223-6
38. 3H]dihydroartemisinin by erythrocytes infected with Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg 1984; 78 (2): 265-70
39. Asawamahasakda W, Benakis A, Meshnick SR. The interaction of artemisinin with red cell membranes. J Lab Clin Med 1994; 123 (5): 757-62
40. Edwards G, Ward S, Breckenridge A. Interaction of arteether with the red blood cell in vitro and its possible importance in the interpretation of plasma concentrations in vivo. J Pharm Pharmacol 1991; 44: 280-1
41. Li WH, Shu HL, Xu GY, et al. The binding of qinghaosu (artemisinine) and its derivatives to plasma protein [in Chinese]. Acta Pharmacol Sin 1982; 17: 783-6
42. Wanwimolruk S, Edwards G, Ward SA, et al. The binding of the antimalarial arteether to human plasma proteins in vitro. J Pharm Pharmacol 1992; 44 (11): 940-2
43. Mansor SM, Molyneux ME, Taylor TE, et al. Effect of Plasmodium falciparum malaria infection on the plasma concentration of alpha-acid glycoprotein and the binding of quinine in Malawian children. Br J Clin Pharmacol 1991; 32: 317-21
44. Colussi D, Parisot C, Legay F, et al. Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur J Pharm Sci 1999; 9(1): 9-16
45. Yang YZ, Asawamahasakda W, Meshnick SR. Alkylation of human albumin by the antimalarial artemisinin. Biochem Pharmacol 1993; 46 (2): 336-9
46. Yang YZ, Little B, Meshnick SR. Alkylation of proteins by artemisinin: effects of heme, pH, and drug structure. Biochem Pharmacol 1994; 48 (3): 569-73
47. Zhao S. High-performance liquid chromatography determination of artemisinin in human plasma and saliva. Analyst 1987; 112: 661-4
48. Zhao S, Zeng M-Y. Application of precolumn reaction to highperformance liquid chromatography of qinghaosu in animal plasma. Anal Chem 1986; 58: 289-92
49. Muhia DK, Mberu EK, Watkins WM. Differential extraction of artemether and its metabolite dihydroartemisinin from plasma and determination by high-performance liquid chromatography. J Chromatogr A 1994; 660: 196-9
50. Thomas CG, Ward SA. Selective determination, in plasma, of artemether and its major metabolite, dihydroartemisinin, by high performance liquid chromatography with ultraviolet detection. J Chromatogr A 1992; 583: 131-6
51. Samdrenan B, Sioufi A, Godbillon J, et al. Determination artemether and its metabolite dihydroartemisinin in plasma by high-performance liquid chromatography and electrochemical detection in the reductive mode. J Chromatogr B Biomed Sci Appl 1987; 691(1): 145-53
52. Navaratnam V, Mansor SM, Chin LK, et al. Determination of artemether and dihydroartemisinin in blood plasma by highperformance liquid chromatography for application in clinical pharmacological studies. J Chromatogr B Biomed Appl 1995; 669 (2): 289-94
53. Idowu OR, Edwards G, Ward SA, et al. Determination of arteether in blood plasma by high performance liquid chromatography with ultraviolet detection after hydrolyis acid. J Chromatogr A 1989; 493: 125-36
54. Zhou ZM, Anders JC, Chung H, et al. Analysis of artesunic acid and dihydroqinghaosu in blood by high-performance liquid chromatography with reductive electrochemical detection. J Chromatogr A 1987; 414 (1): 77-90
55. Batty KT, Davis TM, Thu LT, et al. Selective high-performance liquid Chromatographic determination of artesunate and alpha- and beta-dihydroartemisinin in patients with falciparum malaria. J Chromatogr B Biomed Appl 1996; 677 (2): 345-50
56. Navaratnam V, Mordi MN, Mansor SM. Simultaneous determination of artesunic acid and dihydroartemisinin in blood plasma by high- performance liquid chromatography for application in clinical pharmacological studies. J Chromatogr B Biomed Sci Appl 1997; 692 (1): 157-62
57. Na-Bangchang K, Congpuong K, Hung LN, et al. Simple highperformance liquid Chromatographic method with electrochemical detection of artesunate and dihydroartemisinin in biological fluids. J Chromatogr B Biomed Sci Appl 1998; 7081(2): 201-7
58. Theoharides AD, Smyth MH, Ashmore RW, et al. Determination of the dihydroqinghaosu by pyrolysis gas chromatography/mass spectrometry. Anal Chem 1988; 60: 115-20
59. Navaratnam V, Mordi MN, Mansor SM, et al. Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers. Br J Clin Pharmacol 1997; 43: 363-5
60. Hassan Alin M, Ashton M, Kihamia CM, et al. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg 1996; 90 (1): 61-5
61. Ashton M, Hai TN, Sy ND, et al. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos 1998; 26 (1): 25-7
62. Khanh NX, de Vries PJ, Ha LD, et al. Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for falciparum malaria. Antimicrob Agents Chemother 1999; 43 (3): 690-2
63. Karbwang J, Na-Bangchang K, Thanavibul A, et al. Plasma concentrations of artemether and its major plasma metabolite, dihydroartemisinin, following a 5-day regimen of oral artemether, in patients with uncomplicated falciparum malaria. Ann Trop Med Parasitol 1998; 92 (1): 31-6
64. van Agtmael MA, Cheng-Qi S, Qing JX, et al. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 1999; 12 (2): 151-8
65. Svensson USH, Sandstrom R, Carlborg O, et al. High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement. Drug Metab Dispos 1999; 27 (2): 227-32
66. Augustijns P, D'Hulst A, van Daele J, et al. Transport of artemisinin and sodium artesunate in Caco-2 intestinal epithelial cells. J Pharm Sci 1996; 85 (6): 577-9
67. Titulaer HA, Zuidema J, Lugt CB. Formulation and pharmacokinetics of artemisinin and its derivatives. Int J Pharm 1991; 69: 83-92
68. Lee IK, Hufford CD. Metabolism of antimalarial sesquiterpene lactones. Pharmacol Ther 1990; 48: 345-55
69. Maggs JL, Bishop LP, Edwards G, et al. Biliary metabolites of beta-artemether in rats: biotransformations of an antimalarial endoperoxide. Drug Metab Dispos 2000; 28 (2): 209-17
70. Chi HT, Ramu K, Baker JK, et al. Identification of the in vivo metabolites of the antimalarial arteetherby thermospray highperformance liquid chromatography/mass spectrometry. Biol Mass Spectrom 1991; 20: 609-28
71. Leskovac V, Theoharides AD. Hepatic metabolism of artemisinin drugs-I: drug metabolism in rat liver microsomes. Comp Biochem Physiol 1991; 99C: 383-90
72. Zhu DY, Huang BS, Chen ZL, et al. Isolation and identification of the metabolite of artemisinine in human [in Chinese]. Acta Pharmacol Sin 1983; 4: 194-7
73. Maggs JL, Batty KT, Ilett KF, et al. Isomerization in human urine of a glucuronide of the antimalarial endoperoxide drug dihydroartemisinin [abstract]. Proceedings of the British Pharmacological Society; 1998 Apr 22-24; Chester
74. Yang SD, Ma JM, Sun JH, et al. A preliminary study on the urinary excretion of artesunate and its metabolites in man after a single intravenous injection [in Chinese]. Acta Pharmacol Sin 1987; 22: 401-4
75. Taylor P. Anticholinesterase agents. In: Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 110-5
76. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996; 24 (5): 449-59
77. Ashton M, Johansson L, Thornqvist AS, et al. Quantitative in vivo and in vitro sex differences in artemisinin metabolism in rat. Xenobiotica 1999; 29 (2): 195-204
78. Svensson US, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 1999; 48 (4): 528-35
79. Grace JM, Aguilar AJ, Trotman KM, et al. Metabolism of βarteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab Dispos 1998; 26 (4): 313-7
80. van Agtmael MA, van der Graaf CA, Dien TK, et al. The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet 1998; 23 (3): 429-36
81. Gonzalez FJ. The CYP2D subfamily. In: loannides C, editor. Cylochrome P450: metabolic and toxicological aspects. Boca Raton (FL): CRC Press, 1996: 183-210
82. Richardson TH, Johnson EF. The CYP2C subfamily. In: Ioannides C, editor. Cytochrome P450: metabolic and toxicological aspects. Boca Raton (FL): CRC Press, 1996: 161-81
83. van Agtmael MA, Gupta V, van der Wosten TH, et al. Grapefruit juice increases the bioavailability of artemether. Eur J Clin Pharmacol 1999; 55 (5): 405-10
84. van Agtmael MA, Gupta V, van der Graaf, CA, et al. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther 1999; 66 (4); 408-14
85. Leskovac V, Theoharides AD. Hepatic metabolism of artemisinin drugs: I. Drug metabolism in rat liver microsomes. Comp Biochem Physiol 1991; 99C: 383-90
86. de Waziers I, Cugnenc PH, Yang CS, et al. Cytochrome P450 isoenzymes epoxide hydrolase and glutathiohe transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253 (1): 387-94
87. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampicin-inducible P450IIIA4 in human small bowel enterocytes. J Clin Invest 1992; 90 (5): 1871-8
88. Grace JM, Skanchy DJ, Aguilar AJ. Metabolism of artelinic acid to dihydroqinghaosu by human liver cytochrome P4503A. Xenobiotica 1999; 29 (7): 703-17
89. Svensson USH, Ashton M, Hai TN, et al. Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 1998; 64: 160-7
90. Leo KU, Grace JM, Li Q, et al. Effects of Plasmodium berghei infection on artemether metabolism and disposition. Pharmacology 1997; 54:276-84
91. Kokwaro GO, Glazier AP, Ward SA, et al. Effect of malaria infection and endotoxin-induced fever on phenacelin Odeethylation by rat liver microsomes. Biochem Pharmacol 1993: 45(6): 1235-41
92. Alvares AP, Veng TH, Scheibel LW, et al. Impairment of hepatic cytochrome P450 dependent mono-oxygenase by malarial parasites Plasmodium berghei. Mol Biochem Parasitol 1984; 13: 277-82
93. Mansor SM, Edwards G, Roberts PJ, et al. The effect of malaria infection on paracetamol disposition in the rat. Biochem Pharmacol 1991:41: 1707-11
94. Ismail S, Kokwaro GO, Back DJ, et al. Effect of malaria infection on the pharmacokinetics of paracetamol in rat. Xenobiotica 1994; 24: 527-33
95. Na-Bangchang K, Karbwang J, Thomas CG, et al. Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria. Br J Clin Pharmacol 1994; 37: 249-53
96. Karbwang J, Na-Bangchang K, Tin T, et al. Pharmacokinetics of intramuscular artemether in patients with severe falciparum malaria with or without acute renal failure. Br J Clin Pharmacol 1998; 45: 597-600
97. Duc DD, de Vries PJ, Nguyen XK, et al. The pharmacokinetics of a single dose of artemisinin in healthy Vietnamese subjects. Am J Trop Med Hyg 1994; 51 (6): 785-90
98. de Vries PJ, Nguyen XK, Tran KD, et al. The pharmacokinetics of a single dose of artemisinin in subjects with liver cirrhosis: Bach Mai-Amsterdam Research Group on Artemisinin. Trop Med Int Health 1997; 2(10): 957-62
99. Dien TK, de Vries PJ, Khanh NX, et al. Effect of food intake on the pharmacokinetics of oral artemisinin in healthy Vietnamese subjects. Antimicrob Agents Chemother 1997; 41 (5): 1069-72
100. White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today 1996; 12(10): 399-401
101. Bunnag D, Viravan C, Looareesuwan S, et al. Clinical trial of artesunate and artemether on multidrug resistant falciparum malaria in Thailand: a preliminary report. Southeast Asian J Trop Med Pub Health 1991; 22: 380-5
102. Looareesuwan S, Viravan C, Vanijanonta S, et al. Randomized trial of mefloquine-doxycycline, and artesunate-doxycycline for treatment of acute uncomplicated falciparum malaria. Am J Trop Med Hyg 1994; 50 (6): 784-9
103. Duarte EC, Fontes CJ, Gyorkos TW, et al. Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil. Am J Trop Med Hyg 1996; 54 (2): 197-202
104. Na-Bangchang K, Tippanangkosol P, Ubalee R, et al. Comparative clinical trial of four regimens of dihydroartemisininmefloquine in multidrug-resistant falciparum malaria. Trop Med Int Health 1999; 4 h(9): 602-10
105. Na-Bangchang K, Karbwang J, Molunto P, et al. Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. Fundam Clin Pharmacol 1995; 9 (6): 576-82
106. Alin MH, Ashton M, Kihamia CM, et al. Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Br J Clin Pharmacol 1996; 41 (6): 587-92
107. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine: focus on recent advancements. Clin Pharmacokinet 1996; 31 (4): 257-74
108. Halliday RC, Jones BC, Smith DA, et al. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 1995; 40 (4): 369-78
109. Baune B, Flinois JP, Furlan V, et al. Halofantrine metabolism in microsomes in man: major role of CYP3A4 and CYP3A5. J Pharm Pharmacol 1999; 51 (4): 419-26
110. Zhao XJ, Ishizaki T. The in vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes. J Pharmacol Exp Ther 1997; 283 (3): 1168-76
111. Lin JH, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997; 49 (4): 403-49
112. Na-Bangchang K, Karbwang J, Back DJ. Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol 1992; 44 (3): 587-90
113. Na-Bangchang K, Karbwang J, Back DJ. Mefloquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol 1992; 43 (9): 1957-61
114. van Vugt M, Edstein MD, Proux S, et al. Absence of an interaction between artesunate and atovaquone-proguanil. Eur J Clin Pharmacol 1999; 55: 469-74
115. Tan-ariya P, Na-Bangchang K, Ubalee R, et al. Pharmacokinetic interactions of artemether and pyrimethamine in healthy male Thais. Southeast Asian J Trop Med Public Health 1998; 29 (1): 18-23
116. Na-Bangchang K, Tippawangkosol P, Thanavibul A, et al. Pharmacokinetic and pharmacodynamics interactions of mefloquine and dihydroartemisinin. Int J Clin Pharmacol Res 1999; 19(1): 9-17
117. Lefevre G, Bindschedler M, Ezzet F, et al. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur J Pharm Sci 2000; 10 (2): 141-51
118. Zhao KC, Song ZY. Pharmacokinetics of dihydroqinghaosu in human volunteers and comparison with qinghaosu [in Chinese]. Acta Pharmacol Sin 1993; 28 (5): 342-6
119. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341: 603-8
120. Kamchonwongpaisan S, Vanitchareon N, Yuthavong Y. The mechanism of antimalarial action of artemisinin (Qinghaosu). In: Ong A, Sa H, Packer L, editors. Lipid-soluble antioxidants: biochemistry and clinical applications. Basel: Birkhauser-Verlag, 1992: 363-72
121. Kamchonwongpaisan S, Meshnick SR. The mode of action of the antimalarial artemisinin and its derivatives. Gen Pharmacol 1996; 27 (4): 587-92
122. Robert A, Meunier B. Is alkylation the main mechanism of action of the antimalarial drug artemisinin? Chem Soc Rev 1998; 27:273-9
123. Haynes RK, Hung-On Pai H, Voerste A. Ring opening of artemisinin (Qinghaosu) and dihydroartemisinin and interception of the open hydroperoxides with formation of N-oxides: a chemical model for antimalarial mode of action. Tetrahedon Lett 1999; 40: 4715-8